×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:SYBX

Synlogic Stock Forecast, Price & News

$1.06
-0.09 (-7.83%)
(As of 07/1/2022 08:45 PM ET)
Add
Compare
Today's Range
$1.06
$1.18
50-Day Range
$0.89
$1.85
52-Week Range
$0.88
$4.22
Volume
38,900 shs
Average Volume
128,675 shs
Market Capitalization
$74.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.80

Synlogic MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
635.8% Upside
$7.80 Price Target
Short Interest
Healthy
0.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Synlogic in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$28.28 K Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.90) to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.02 out of 5 stars

Medical Sector

473rd out of 1,412 stocks

Pharmaceutical Preparations Industry

221st out of 673 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SYBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

Synlogic logo

About Synlogic (NASDAQ:SYBX) Stock

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

SYBX Stock News Headlines

Synlogic, Inc. (NASDAQ:SYBX) Short Interest Down 18.1% in May
Synlogic Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYBX
Employees
84
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/03/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$7.80
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+635.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
5 Analysts

Profitability

Net Income
$-60.56 million
Net Margins
-3,067.42%
Pretax Margin
-3,067.42%

Debt

Sales & Book Value

Annual Sales
$1.75 million
Book Value
$2.11 per share

Miscellaneous

Free Float
65,952,000
Market Cap
$74.47 million
Optionable
Not Optionable
Beta
1.45














Synlogic Frequently Asked Questions

Should I buy or sell Synlogic stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic
or view top-rated stocks.

What is Synlogic's stock price forecast for 2022?

5 equities research analysts have issued 1 year price targets for Synlogic's stock. Their SYBX stock forecasts range from $6.00 to $9.00. On average, they predict Synlogic's stock price to reach $7.80 in the next year. This suggests a possible upside of 635.8% from the stock's current price.
View analysts' price targets for Synlogic
or view top-rated stocks among Wall Street analysts.

How has Synlogic's stock performed in 2022?

Synlogic's stock was trading at $2.42 at the beginning of 2022. Since then, SYBX shares have decreased by 56.2% and is now trading at $1.06.
View the best growth stocks for 2022 here
.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Synlogic
.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) posted its earnings results on Thursday, May, 12th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. The biotechnology company earned $0.24 million during the quarter, compared to the consensus estimate of $0.50 million. Synlogic had a negative trailing twelve-month return on equity of 43.07% and a negative net margin of 3,067.42%. During the same quarter in the previous year, the business earned ($0.36) EPS.
View Synlogic's earnings history
.

When did Synlogic's stock split? How did Synlogic's stock split work?

Shares of Synlogic reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

Who are Synlogic's key executives?

Synlogic's management team includes the following people:
  • Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc, Pres, CEO & Director (Age 46, Pay $891.42k)
  • Mr. Antoine Awad, Chief Operating Officer (Age 42, Pay $572.92k)
  • Dr. Timothy K. Lu M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 41)
  • Dr. James J. Collins Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 56)
  • Mr. Michael Jensen, Chief Financial Officer
  • Dr. David L. Hava Ph.D., Chief Scientific Officer (Age 47)
  • Dr. Elizabeth Wolffe, Head of Investor Relations & Corp. Communications
  • Mr. Daniel Rosan, Sr. VP & Head of Investor Relations
  • Mr. Brendan St. Amant, Head of Legal
  • Mr. Adam Thomas, Chief People Officer & Sec.

What other stocks do shareholders of Synlogic own?

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $1.06.

How much money does Synlogic make?

Synlogic (NASDAQ:SYBX) has a market capitalization of $74.47 million and generates $1.75 million in revenue each year. The biotechnology company earns $-60.56 million in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Synlogic have?

Synlogic employs 84 workers across the globe.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The official website for Synlogic is www.synlogictx.com. The biotechnology company can be reached via phone at (617) 401-9975, via email at liz@synlogictx.com, or via fax at 512-681-5201.

This page (NASDAQ:SYBX) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.